NTRA - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 27, 2026
5.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Management expresses caution regarding future financing needs and the potential impact of not securing adequate capital.. Significant ongoing litigation with substantial potential exposure, including a $292.5 million verdict in a false advertising case against Guardant Health, with a pending appeal.. Revenue increased by 35.9% to $2,306.1 million in 2025 from $1,696.9 million in 2024.

Top Concerns

  • !Reimbursement challenges and in-network contract impacts on gross margins remain a concern.
  • !Company's net loss of $208.2 million for the year ended December 31, 2025, and an accumulated deficit of $2.8 billion as of December 31, 2025, raise concerns about its long-term viability without addi...
  • !The company's ability to continue as a going concern is dependent on securing additional financing, highlighting significant liquidity risks.
  • !Significant ongoing litigation with substantial potential exposure, including a $292.5 million verdict in a false advertising case against Guardant Health, with a pending appeal.
  • !Material contractual commitments totaling $256.9 million over the next several years, including significant obligations to material suppliers ($107.3M) and cloud platform providers ($28.0M).

Top Positives

  • +The company is experiencing significant revenue growth (35.9% YoY in 2025), primarily driven by product revenues and increased test volumes.
  • +Despite revenue growth, the company continues to incur net losses and expects to do so in the future, relying on external financing.
  • +The company is investing heavily in R&D (up 54.4%) and SG&A (up 39.9%), indicating a focus on growth and market expansion.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

6.0/10

Management tone is cautiously measured with focus on average selling price improvements.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate with $256.942M in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows reimbursement and payer decisions for key tests as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

MRNA 10-K Analysis: The 78% Margin Platform Hidden Behind -158% Operating Losses

Analysis

NTRA 10-K Analysis: The $135M Revenue Catch-Up Behind Natera's 36% Growth